Filing Analysis
Editas Medicine announced the resignation of Board Director Elliott Levy, M.D., and the appointment of Patrick Ellinor, M.D., Ph.D., as an independent director. The company also furnished its Q2 2026 financial results via press release.
🚩 Red Flags
- None identified in this filing; the director's resignation was explicitly stated as not being due to a disagreement with operations or policies.
📋 Key Facts
- Elliott Levy, M.D. resigned from the Board effective August 4, 2026; resignation was not due to any disagreement with the Company.
- Patrick Ellinor, M.D., Ph.D. appointed as an independent director (Class I) effective August 6, 2026.
- Dr. Ellinor holds leadership roles at Mass General Brigham and the Broad Institute of Harvard and MIT.
- Dr. Ellinor's compensation includes $40,000 annual cash and an option to purchase 103,400 shares of common stock vesting over three years.
- Company issued Q2 2026 financial results on August 5, 2026.
Editas Medicine reported the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. The stockholders elected two Class I directors, approved executive compensation on an advisory basis, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor.
📋 Key Facts
- Bernadette Connaughton and Elliott Levy, M.D. were elected as Class I directors until 2029.
- Executive compensation was approved on an advisory basis with 32,914,258 votes for and 6,322,885 votes against.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The meeting took place on June 17, 2026.
Editas Medicine entered into an underwriting agreement on May 26, 2026, for a public offering of 55,555,556 shares of common stock and an equal number of accompanying common stock warrants. The company expects net proceeds of approximately $117.0 million, with potential additional proceeds of $192.5 million if all warrants are exercised.
🚩 Red Flags
- Significant dilution: The issuance of 55.5 million shares plus an equal number of warrants creates massive potential dilution for existing shareholders.
- Highly structured offering: The use of warrants with specific clinical trial triggers (EDIT-401) suggests a complex financing arrangement often seen in distressed or high-risk micro-cap biotech companies.
- Low offering price: The offering price of $2.25 is significantly lower than the the warrant exercise price of $3.50, indicating a high degree of investor skepticism regarding current valuation.
📋 Key Facts
- Offering consists of 55,555,556 shares of common stock and 55,555,556 common stock warrants.
- Combined public offering price is $2.25 per share/warrant unit.
- Estimated net proceeds from the initial offering are $117.0 million.
- Potential additional proceeds from warrant exercises are $192.5 million.
- Warrants have an exercise price of $3.50 per share.
- Warrants expire on the earlier of: (i) 30 days after public announcement of Phase 1 clinical data for EDIT-401 showing >80% LDL-cholesterol reduction in at least 3 patients, or (ii) three years from issuance.
- Company estimates that proceeds plus existing cash as of March 31, 2026, will fund operations into the second half of 2028.
Editas Medicine announced the suspension and termination of its current prospectus supplement for its at-the-market (ATM) offering program with TD Cowen, while maintaining the overall Sales Agreement.
📋 Key Facts
- The Company notified TD Securities (USA) LLC (TD Cowen) of the suspension and termination of the prospectus supplement dated March 21, 2025.
- The Company will not sell more shares under the ATM program until a new prospectus or registration is filed.
- As of May 26, 2026, the Company has sold 14,327,365 shares for aggregate gross proceeds of $43.9 million.
- The Sales Agreement itself remains in full force and effect.
Editas Medicine announced preclinical data for its lead in vivo candidate, EDIT-401, showing robust reductions in LDL-C, Lp(a), and ApoB in non-human primates. The company plans to initiate a first-in-human clinical trial in Australia in late 2026 for patients with Heterozygous Familial Hypercholesterolemia (HeFH).
📋 Key Facts
- EDIT-401 achieved a 90% or greater mean reduction in LDL-C, Lp(a), and ApoB in non-human primates (NHPs) with durability through six months.
- Therapeutically relevant dose of 1.5 mg/kg was well-tolerated with no adverse clinical observations or liver histopathology findings.
- Higher doses (3 mg/kg and 6 mg/kg) showed minimal to marked liver enzyme increases and one adverse clinical observation at 6 mg/kg.
- Plan to submit a Clinical Trial Notification (CTN) in Australia to the TGA in mid-2026.
- Goal to initiate first-in-human clinical trial in patients with HeFH later in 2026.
- Expects early in vivo human proof of concept data by the end of 2026.
- Phase 1/2 trial design: Part 1 (single ascending dose, ~18 patients) and Part 2 (randomized, placebo-controlled expansion, ~28 patients).
- Received pre-IND feedback from the FDA regarding nonclinical package and CMC plans.
Editas Medicine reported positive preclinical data for its lead in vivo candidate, EDIT-401, at the ASGCT 2026 Annual Meeting. The data demonstrated significant and durable LDL cholesterol reduction in non-human primates and mice, supporting its potential as a one-time treatment for hyperlipidemia.
📋 Key Facts
- EDIT-401 achieved 90% or greater mean LDL cholesterol (LDL-C) reduction across all dose groups in non-human primates.
- LDL-C lowering remained durable through approximately six months of evaluation.
- The reduction was achieved with 10-40% functional editing of LDLR alleles and a six-fold or greater increase in hepatic LDLR protein.
- No adverse clinical observations were noted at the therapeutically relevant dose of 1.5 mg/kg.
- Data suggests that dose adjustments may not be required to achieve LDL-C lowering in heterozygous familial hypercholesterolemia (HeFH) patients.
Editas Medicine, Inc. reported its financial results for the first quarter ended March 31, 2026. The filing serves as a formal vehicle to furnish the quarterly earnings press release and business highlights to the SEC.
📋 Key Facts
- The report was filed on May 5, 2026, covering the fiscal quarter ended March 31, 2026.
- The company furnished a press release as Exhibit 99.1 detailing results of operations and financial condition.
- The filing was signed by Amy Parison, Chief Financial Officer.
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Editas Medicine, Inc. dismissed Ernst & Young LLP and appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2026. The transition was approved by the Audit Committee following a formal review process and reported no disagreements or accounting issues.
📋 Key Facts
- Dismissal of Ernst & Young LLP occurred on April 1, 2026.
- PricewaterhouseCoopers LLP was appointed as the new auditor for the fiscal year ending December 31, 2026.
- Ernst & Young's audit reports for the fiscal years ended December 31, 2024, and December 31, 2025, contained no adverse opinions or qualifications.
- There were no 'disagreements' or 'reportable events' as defined by SEC regulations during the fiscal years 2024, 2025, or the subsequent interim period through April 1, 2026.
- The company provided EY with a copy of the disclosure and filed EY's letter of agreement as Exhibit 16.1.
Editas Medicine announced that the U.S. Patent and Trademark Office (USPTO) reaffirmed a prior decision favoring the Broad Institute in a foundational CRISPR/Cas9 patent interference case. This ruling supports the validity of the core intellectual property licensed by Editas for human therapeutic applications against challenges from the University of California and others.
🚩 Red Flags
- Potential for further litigation delay as the opposing party (CVC) retains the right to appeal the decision to the CAFC.
📋 Key Facts
- On March 26, 2026, the USPTO reaffirmed the Patent Trial and Appeal Board's (PTAB) decision in favor of the Broad Institute.
- The interference involves patents for CRISPR/Cas9 editing in human cells between CVC (University of California, University of Vienna, and Emmanuelle Charpentier) and the Broad Institute (including MIT and Harvard).
- The decision followed a remand from the U.S. Court of Appeals for the Federal Circuit (CAFC) after a May 2025 ruling.
- CVC retains the right to appeal this reaffirmed decision to the CAFC.
Editas Medicine announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The filing serves as a formal vehicle to furnish the earnings press release and provide business highlights to the public.
📋 Key Facts
- Financial results cover the fiscal quarter and year ended December 31, 2025
- Press release issued and furnished as Exhibit 99.1 on March 9, 2026
- Report signed by Amy Parison, Chief Financial Officer
- The information is furnished under Item 2.02 and not deemed 'filed' for Section 18 purposes
Editas Medicine, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings and business highlights.
📋 Key Facts
- Report date: November 10, 2025
- Reporting period: Fiscal quarter ended September 30, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Signed by Amy Parison, Chief Financial Officer
Editas Medicine reported positive in vivo preclinical proof-of-concept data for its EDIT-401 therapy at the ESGCT 32nd Annual Congress. The data demonstrates significant LDL-cholesterol reductions in non-human primates and mice using CRISPR/Cas9 technology.
📋 Key Facts
- Reported in vivo preclinical proof-of-concept data for EDIT-401, a potential one-time therapy to reduce LDL-cholesterol via LDLR upregulation.
- In non-human primates, EDIT-401 achieved LDL-C reductions of ≥90% within 48 hours of a single dose.
- Achieved ≥90% LDL-C reduction in mice with high baseline LDL-C and reduced LDLR function; reductions were maintained over three months.
- Observed at least a six-fold mean increase in LDLR protein in the non-human primate liver.
- Therapeutic mechanism involves CRISPR/Cas9 nuclease and dual guide RNAs via lipid nanoparticle delivery to disrupt negative regulatory elements in the 3' UTR.
Editas Medicine has nominated EDIT-401, an in vivo gene editing therapy targeting LDLR to treat hyperlipidemia, as its lead development candidate. The company is shifting resources from its Hematopoietic Stem Cells program to focus on advancing EDIT-401 toward human proof-of-concept.
🚩 Red Flags
- Resource reallocation: The company is deprioritizing its Hematopoietic Stem Cells program to focus on the lead candidate, indicating a narrowing of pipeline breadth.
📋 Key Facts
- Nominated EDIT-401 (LDLR-targeted) as the lead in vivo development candidate.
- Preclinical non-human primate studies showed ~90% mean reduction of LDL-C levels and a six-fold increase in LDLR protein levels.
- Planned milestone: Submit IND/CTA for EDIT-401 by mid-2026.
- Goal: Achieve in vivo human proof-of-concept data for EDIT-401 by end of 2026.
- Company expects to identify an additional target cell type or tissue by the end of 2025.
- Cash runway guidance re-confirmed through Q2 2027, supported by existing cash and Vertex Pharmaceuticals license payments.
Editas Medicine, Inc. filed an 8-K to announce its financial results and business highlights for the fiscal quarter ended June 30, 2025.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Fiscal quarter ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and business highlights.
- Information under Item 2.02 is furnished but not filed for purposes of Section 18 liability.
Editas Medicine announced positive non-human primate (NHP) data regarding its proprietary targeted lipid nanoparticle (tLNP) delivery system. The study demonstrated 58% mean on-target editing in the HBG1/2 promoter region of hematopoietic stem cells, exceeding the therapeutic threshold.
📋 Key Facts
- Announced results from an ongoing NHP study involving a single intravenous dose of proprietary tLNP.
- Achieved mean on-target editing levels of 58% in the HBG1/2 promoter region of HSCs at five months.
- The observed 58% editing level exceeds the predicted therapeutic threshold of ≥25%.
- Biodistribution data indicated significant de-targeting of the liver compared to standard LNPs.
Editas Medicine reported the results of its 2025 Annual Meeting of Stockholders held on May 29, 2025. The meeting included the election of two directors and approval of several material amendments to corporate governance documents and incentive plans.
🚩 Red Flags
- Significant increase in authorized shares (from 200M to 395M), which provides the company with substantial capacity for future equity dilution through secondary offerings or warrant exercises.
📋 Key Facts
- Stockholders approved an amendment and restatement of the 2015 Stock Incentive Plan (Amended 2015 Plan).
- The Amended 2015 Plan extends the plan term to ten years and eliminates the 'evergreen' provision.
- Stockholders approved an amendment to the Certificate of Incorporation to increase authorized shares from 200,000,000 to 395,000,000.
- Jessica Hopfield, Ph.D., and David Scadden, M.D., were elected as Class III directors until 2028.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the current fiscal year.
- Advisory votes approved executive compensation (Say-on-Pay) and a one-year frequency for future Say-on-Pay votes.
Editas Medicine announced positive in vivo data regarding its gene upregulation strategy using proprietary targeted lipid nanoparticles (tLNP). The data showed therapeutically relevant HBG1/2 promoter editing levels in both humanized mice and non-human primates.
📋 Key Facts
- Achieved up to 47% HBG1/2 editing levels in an ongoing NHP study via a single intravenous dose of proprietary tLNP.
- Achieved 48% editing of HBG1/2 in long-term HSCs in humanized mice following a single dose.
- Both studies exceeded the predicted therapeutic threshold of ≥25% editing.
- Preliminary biodistribution data in NHPs indicates significant de-targeting of the liver compared to standard LNPs.
Editas Medicine announced positive in vivo proof-of-concept data for an undisclosed liver target using CRISPR/Cas RNA cargo delivered via lipid nanoparticles (LNPs). The data showed significant gene editing and biomarker reduction in both mouse models and cynomolgus monkeys.
📋 Key Facts
- Reported in vivo editing strategy using LNPs with CRISPR/Cas RNA cargo for an undisclosed liver target.
- Mouse model results: ~70% maximal liver editing of the target gene and >80% reduction in disease-specific biomarker.
- Cynomolgus monkey results: >50% target gene editing and >15-fold protein upregulation in hepatocytes.
- The strategy aims to mimic a protective natural variant to upregulate a specific target gene.
Editas Medicine, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal mechanism to furnish quarterly business highlights and financial performance data via a press release.
📋 Key Facts
- Report date: May 12, 2025
- Reporting period: Fiscal quarter ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) containing financial results and business highlights.
- The information in Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Editas Medicine announced the resignation of its CFO, Erick Lucera, effective March 28, 2025. The company has appointed Amy Parison as the new CFO and Treasurer, effective concurrently with Mr. Lucera's departure.
🚩 Red Flags
- Sudden departure of a key C-suite officer (CFO) with a short notice period (announced March 18, effective March 28).
📋 Key Facts
- Erick Lucera (EVP, CFO) is resigning effective March 28, 2025.
- Amy Parison (SVP, Finance) appointed as SVP, CFO and Treasurer effective March 28, 2025.
- Ms. Parison's new compensation includes a $415,000 annual base salary and a 40% target bonus.
- A promotion option for 34,672 shares will be granted to Ms. Parison on April 8, 2025, vesting over 48 months.
- Ms. Parison previously held leadership roles at Vertex Pharmaceuticals and Rubius Therapeutics.
Editas Medicine, Inc. filed an 8-K to announce its financial results for the fiscal quarter and year ended December 31, 2024. The filing serves as a formal vehicle to furnish the company's quarterly press release.
📋 Key Facts
- Report date: March 5, 2025
- Reporting period: Fiscal quarter and year ended December 31, 2024
- The filing includes a press release as Exhibit 99.1 containing financial results and business highlights.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Editas Medicine disclosed preliminary unaudited cash and marketable securities totaling approximately $270 million as of December 31, 2024. The company also issued a press release regarding preclinical data and strategic priorities.
📋 Key Facts
- Preliminary unaudited cash, cash equivalents, and marketable securities: ~$270 million (as of Dec 31, 2024).
- Company announced new in vivo preclinical proof of concept data via press release.
- Announced anticipated 2025 key milestones and three-year strategic priorities.
Editas Medicine, Inc. announced a separation agreement for Baisong Mei, the current Executive Vice President and Chief Medical Officer. Dr. Mei is scheduled to transition out of his role by January 31, 2025.
🚩 Red Flags
- Departure of a key C-suite executive (Chief Medical Officer) in the biotech sector can signal internal shifts or strategic changes.
📋 Key Facts
- Dr. Baisong Mei will step down as Chief Medical Officer effective December 31, 2024.
- A separation agreement was entered into on December 16, 2024.
- The transition/separation period ends on January 31, 2025.
- Severance includes base salary for 12 months following the Separation Date and COBRA health care contributions.
- Unpaid annual bonus for 2024 will be determined by the Board.
- Vested stock options exercise period is extended to December 31, 2025.
- Time-based RSUs will continue to vest for 90 days following the Separation Date.
Editas Medicine is discontinuing the clinical development of its 'reni-cel' program for sickle cell disease and beta thalassemia. This strategic pivot involves a massive 65% workforce reduction to refocus on in vivo gene editing.
🚩 Red Flags
- Massive workforce reduction (65% of staff) indicates significant distress or radical restructuring.
- Discontinuation of a major clinical program (reni-cel).
- Termination of previously announced efforts to partner or out-license the reni-cel asset.
- Departure of Chief Medical Officer Baisong Mei effective Dec 31, 2024.
- Resignation of two Board members: Emma Reeve and Meeta Chatterjee, Ph.D.
📋 Key Facts
- Discontinuation of ex vivo reni-cel program (sickle cell/beta thalassemia).
- Workforce reduction of approximately 180 positions, representing ~65% of the company's employees.
- Estimated discontinuation costs: $55.0 million to $70.0 million.
- Estimated severance and benefit costs: $14.0 million to $18.0 million.
- Strategic pivot from ex vivo to in vivo gene editing development.
- Cash runway expected to be extended into Q2 2027 due to cost-containment measures.
Editas Medicine filed an 8-K to report amendments to its corporate bylaws and the release of updated clinical data from the RUBY Trial regarding Reni-cel for Sickle Cell Disease.
📋 Key Facts
- The Board of Directors unanimously adopted Amended and Restated By-Laws effective December 6, 2024.
- Bylaw changes include clarifying the definition of 'acting in concert' per Rule 14a-19.
- Company issued a press release on December 9, 2024, regarding updated clinical data from the RUBY Trial for Reni-cel.
- The clinical data pertains to patients with Severe Sickle Cell Disease presented at the ASH Annual Meeting.
Editas Medicine, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2024, and other business highlights.
📋 Key Facts
- Report date: November 4, 2024
- Reporting period: Fiscal quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results and business highlights.
- Information under Item 2.02 is furnished but not filed for purposes of Section 18 liability.
Editas Medicine provided a preliminary update on its financial position and issued a strategic press release regarding preclinical progress. The company reported approximately $265 million in cash, cash equivalents, and marketable securities as of September 30, 2024.
📋 Key Facts
- Preliminary unaudited cash, cash equivalents, and marketable securities: ~$265 million (as of Sept 30, 2024).
- Company achieved 'In Vivo' preclinical proof of concept as per the referenced press release.
- The financial information provided is preliminary and subject to third-quarter closing procedures.
Editas Medicine entered into a purchase and sale agreement with a subsidiary of DRI Healthcare Trust to sell up to 100% of certain future license fee receivables from Vertex Pharmaceuticals for an upfront cash payment of $57.0 million.
🚩 Red Flags
- Sale of future receivables is often a liquidity-driven move used by biotech companies to extend cash runway without issuing more equity or debt.
- Potential for liquidated damages/termination fees in the range of 1x to 2x the upfront payment ($57M - $114M) under specified circumstances.
📋 Key Facts
- Upfront cash payment: $57.0 million received on October 3, 2024.
- Asset sold: Future fixed and sales-based annual license fees owed by Vertex Pharmaceuticals under a Cas9 gene-editing technology license agreement.
- Estimated annual fee range: $5.0 million to $40.0 million per year.
- The deal includes a mid-double-digit percentage of a potential $50.0 million contingent upfront payment from Vertex.
- The purchaser (DRI Healthcare Trust subsidiary) has no recourse to Editas assets other than the purchased receivables.
- Editas retains obligations to pay licensors (Broad Institute and Harvard) from these proceeds.
Editas Medicine, Inc. issued an 8-K to announce its financial results for the fiscal quarter ended June 30, 2024, and provided various business highlights via a press release.
📋 Key Facts
- Report date: August 7, 2024
- Reporting period: Fiscal quarter ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results and business highlights.
- Information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Editas Medicine, Inc. announced the resignation of Akshay Vaishnaw from its Board of Directors, effective June 30, 2024. The company explicitly stated that the resignation was not due to any disagreements regarding operations, policies, or practices.
📋 Key Facts
- Akshay Vaishnaw resigned from the Board of Directors on June 27, 2024.
- The resignation is effective as of June 30, 2024.
- The departure was not due to any disagreement with the Company's operations, policies, or practices.
Editas Medicine announced positive clinical data updates for its gene-editing therapy, reni-cel, across two trials: RUBY (Sickle Cell Disease) and EdiTHAL (Beta Thalassemia). The data shows high levels of hemoglobin normalization and transfusion independence in patients with no reported serious adverse events related to the treatment.
📋 Key Facts
- RUBY Trial (SCD): 18 patients showed no vaso-occlusive events; mean total Hb at month six was 14.3 g/dL for nine patients.
- EdiTHAL Trial (TDT): All 7 patients have been transfusion free for 4.1 to 12.8 months post-infusion.
- Safety: No serious adverse events related to reni-cel treatment were reported in either trial; safety profile was consistent with standard myeloablative conditioning.
- Efficacy: Sustained high levels of editing in HBG1 and HBG2 promoter regions observed across all patients.
Editas Medicine, Inc. reported the results of its Annual Meeting of Stockholders held on May 30, 2024. The meeting included the election of three Class II directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual Meeting of Stockholders held on May 30, 2024.
- Elected Meeta Chatterjee, Ph.D., Andrew Hirsch, and Gilmore O’Neill, M.B. to Class II directors until the 2027 Annual Meeting.
- Stockholders approved executive compensation on an advisory basis (Say-on-Pay) with 38,609,828 votes in favor.
- Ratified Ernst & Young LLP as the independent registered public accounting firm for the current fiscal year with 57,952,408 votes in favor.
Editas Medicine, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024 and provided various business highlights.
📋 Key Facts
- Reporting period: Fiscal quarter ended March 31, 2024
- Filing date: May 8, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and business highlights.
Editas Medicine, Inc. filed an 8-K to announce its financial results for the fiscal quarter and year ended December 31, 2023. The filing serves as a formal mechanism to furnish quarterly earnings data via a press release.
📋 Key Facts
- Report date: February 28, 2024
- Reporting period: Fiscal quarter and year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the earnings press release
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability